Clinical trials: Hepatic Chemotherapy
Colorectal Liver Metastases, Colorectal Cancer
Patient Outcomes After Hepatic Artery Infusion Pump Placement
The purpose of this study is to evaluate the surgical outcomes and the quality of life (QOL) in patients undergoing hepatic artery infusion pump placement for colorectal liver metastases (CRLM).
- Trial name
- NCT05468593
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Mayo Clinic
Hepatocellular Carcinoma
HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC
To Evaluate the Efficacy and Safety of the Hepatic Arterial Infusion Chemotherapy(HAIC) Combined With Sintilimab and Bevacizumab Biosimilar in the Treatment of Patients With Unresectable Hepatocellular Carcinoma.
- Trial name
- NCT05029973
- Testing
- HAIC, Sintilimab, Bevacizumab Biosimilar
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hepatic Arterial Infusion Chemotherapy, Liver Metastases
HAIC Combined Sintilimab for Liver Metastasis From Esophageal Squamous Cell Carcinoma
Patients with liver metastasis from esophagus squamous (ESC) are usually offered systemic therapy. However, for those with predominant liver disease or failure of system therapy, local liver management becomes an option.
- Conditions
- Hepatic Arterial Infusion Chemotherapy, Liver Metastases, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT06184841
- Testing
- HAIC combined with intravenous PD-1
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Peking University Cancer Hospital & Institute
HCC - Hepatocellular Carcinoma
Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
The purpose of this study is to learn how well a combination of iparomlimab and tuvonralimab (QL1706), lenvatinib, radiotherapy, and hepatic arterial infusion chemotherapy (HAIC) works and how safe it is for people with…
- Trial name
- NCT07776080
- Testing
- Iparomlimab and Tuvonralimab (QL1706), Lenvatinib, Radiotherapy
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Hepatocellular Carcinoma Non-resectable
DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC
This study is conducted to evaluate the efficacy and safety of transarterial chemoembolization with drug-eluting beads (DEB-TACE) combined with hepatic artery infusion chemotherapy (HAIC) with oxaliplatin and raltitrexed…
- Trial name
- NCT06397235
- Testing
- DEB-TACE+HAIC, DEB-TACE
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Unresectable Hepatocellular Carcinoma
DEB-TACE+HAIC vs. HAIC for Large HCC
This study is conducted to evaluate the efficacy and safety of transarterial chemoembolization with drug-eluting beads (DEB-TACE) plus hepatic artery infusion chemotherapy (HAIC) compared with HAIC alone for unresectable large…
- Trial name
- NCT05263219
- Testing
- dTACE-HAIC, HAIC, dTACE-HAIC protocol
- Where
- China
- Volunteers
- 230 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Pancreatic Neoplasms, Hepatic Metastasis of Pancreatic Cancer
Hepatic Arterial Infusion of Sodium Bicarbonate (NaHCO3) Combined With NASOX Regimen and Programmed Death-1 (PD-1) Inhibitors for Pancreatic Cancer Liver Metastases
This Phase II clinical study evaluates the safety and efficacy of a combination therapy for patients with pancreatic cancer that has spread to the liver.
- Trial name
- NCT07504471
- Testing
- pH-NASOX-Immune Group
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Ruijin Hospital
Intrahepatic Cholangiocarcinoma (Icc), HAIC
Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial)
At present, the first-line treatment for patients with advanced unresectable intrahepatic cholangiocarcinoma is mainly systemic treatment, but the improvement in efficacy is limited and is not enough to meet the current clinical…
- Conditions
- Intrahepatic Cholangiocarcinoma (Icc), HAIC, Durvalumab
- Trial name
- HAIC-quad (NCT06859684)
- Testing
- Durvalumab, hepatic arterial infusion chemotherapy (HAIC), Lenvatinib
- Where
- China
- Volunteers
- 25 people
- Sponsor
- West China Hospital
Hepatocellular Carcinoma
Nocardia Rubra Cell Wall Skeleton (N-CWS) Plus HAIC, Lenvatinib and Tislelizumab in Treating Patients With Advanced HCC
The purpose of this study is to evaluate the efficacy and safety of Nocardia rubra cell wall skeleton plus hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin, lenvatinib and tislelizumab in…
- Trial name
- CCGLC-007 (NCT05533892)
- Testing
- Nocardia rubra cell wall skeleton, Hepatic arterial infusion chemotherapy, Lenvatinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Wan-Guang Zhang
HepatoCellular Carcinoma
HAIC of Oxaliplatin, and 2400 mg/m² 5-fu vs HAIC of Oxaliplatin, and 1200 mg/m² 5-fu for Unresectable HCC: a Randomised Phase 3 Non-inferiority Trial
Hepatic artery infusion of oxaliplatin, leucovorin and 2400 mg/m² fluorouracil is effective in hepatocellular carcinoma. However, SILIUS study showed that sorafenib plus hepatic artery infusion of cisplatin and fluorouracil did…
- Trial name
- NCT04667351
- Testing
- 2400 mg/m² 5-fu, 1200 mg/m² 5-fu
- Where
- 3 sites in China
- Volunteers
- 400 people
- Sponsor
- Sun Yat-sen University
Colorectal Cancer, Metastatic Cancer
Chemotherapy With or Without Isolated Hepatic Perfusion With Melphalan in Treating Patients With Colorectal Cancer That Has Spread to the Liver
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more tumor cells.
- Trial name
- NCT00020501
- Testing
- FOLFIRI regimen, floxuridine, fluorouracil
- Where
- United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Colorectal Neoplasms
Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver
Colorectal cancer is the 3rd most common cancer in France and the 2nd cause of death from cancer. Between 30 to 60% of patients develop limited or predominant liver metastases.
- Trial name
- OSCAR (NCT02885753)
- Testing
- Oxaliplatin intravenous, 5 FU bolus, Folinic acid
- Where
- 49 sites in Belgium, France
- Volunteers
- 348 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Hepatocellular Carcinoma
Donafenib Combine With Sintilimab and HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）in the First-line Treatment of Unresectable Hepatocellular Carcinoma
The investigators design a phase IIB clinical study to explore the efficacy and safety of Donafenib combined with Sintilimab and HAIC in the first-line treatment of unresectable hepatocellular carcinoma
- Trial name
- NCT05166772
- Testing
- Donafenib, Sintilimab, HAIC
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
C-staged Hepatocellular Carcinoma in BCLC Classification
A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification
This study was designed to evaluate the effectiveness and safety of hepatic arterial infusion chemotherapy combined with Apatinib and Camrelizumab (Triplet-combined Therapy) for C-staged Hepatocellular Carcinoma in BCLC…
- Trial name
- TRIPLET (NCT04191889)
- Testing
- Hepatic Arterial Infusion combined with Apatinib and Camrelizumab
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma
The study is being conducted to evaluate the efficacy and safety of conversion treatment of Hepatic Arterial Infusion Chemotherapy combined with Camrelizumab and Apatinib for unresected hepatocellular carcinoma.
- Trial name
- NCT05099848
- Testing
- Camrelizumab
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Shandong Cancer Hospital and Institute
Colorectal Cancer, Pancreatic Cancer
Quality of Life of Patients Over 75 Yars Undergoing Palliative Chemotherapy
The aim of this research is to evaluate the quality of life of patients over 75 years of age undergoing palliative chemotherapy for digestive cancer.
- Conditions
- Colorectal Cancer, Pancreatic Cancer, Biliary Cancer, Hepatic Cancer
- Trial name
- EQLVCPAL (NCT04517448)
- Where
- France
- Volunteers
- 31 people
- Sponsor
- Centre Hospitalier de la côte Basque
HCC - Hepatocellular Carcinoma, Hepatic Arterial Infusion Chemotherapy
HAIC in Combination With PD-1 Inhibitors and Lenvatinib for High Tumor Burden Advanced HCC (CHANCE2416)
The purpose of this study is to evaluate the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) in combination with PD-1 inhibitors and Lenvatinib in patients with high tumor burden advanced-stage hepatocellular…
- Conditions
- HCC - Hepatocellular Carcinoma, Hepatic Arterial Infusion Chemotherapy, BCLC Stage C Hepatocellular Carcinoma, Lenvatinib
- Trial name
- NCT06631326
- Testing
- hepatic artery infusion chemotherapy, Lenvatinib + PD-1 monoclonal antibody
- Where
- China
- Volunteers
- 244 people
- Sponsor
- First Hospital of China Medical University
Histologically-proven and Radiologically-confirmed Solid Tumors
An Open-label, Dose Escalation Study to Assess the Pharmacokinetics of of ASA404 in Adult Cancer Patients With Impaired Hepatic Function
This study is designed to obtain pharmacokinetic data following a single-dose 20-minute i.v. administration of ASA404 (900, 1200, or 1800 mg/m2) in adult cancer patients with varying degrees of hepatic impairment.
- Trial name
- NCT01278849
- Testing
- ASA404
- Where
- 4 sites in Italy, New Zealand
- Volunteers
- 5 people
- Sponsor
- Novartis Pharmaceuticals
Hepatocellular Carcinoma
HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）Plus Sintilimab and Donafenib in the First-line Treatment of Unresectable Hepatocellular Carcinoma
This is a single-arm exploratory clinical study to evaluate the efficacy and safety of HAIC in combination with Sintilimab and Donafenib in patients with BCLC-C stage who have not received prior systemic therapy
- Trial name
- NCT06244225
- Testing
- Donafenib； Sintilimab； HAIC
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Colorectal Liver Metastasis
Hepatic Arterial Infusion Chemotherapy Combined With Sintilimab and Regorafenib as Adjuvant Therapy for Colorectal Liver Metastasis Patients With a High Risk of Recurrent: a Single-arm, Phase II Study
Pts with histologically confirmed CRLM and whose CRS >2 were enrolled into this single-arm, phase II study. The critical enrollment criteria were that Subjects had completely resected Primary lesion and liver metastases and had…
- Trial name
- NCT05753163
- Testing
- HAIC-FOLFOX combined with Sintilimab and Regorafenib
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Fudan University